Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 9, pp. 1117-1145
Open Access | Times Cited: 347

Showing 26-50 of 347 citing articles:

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
Erin D. Michos, George L. Bakris, Helena W. Rodbard, et al.
American Journal of Preventive Cardiology (2023) Vol. 14, pp. 100502-100502
Open Access | Times Cited: 63
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes
Neha J. Pagidipati, Adam J. Nelson, Lisa A. Kaltenbach, et al.
JAMA (2023) Vol. 329, Iss. 15, pp. 1261-1261
Open Access | Times Cited: 56
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S207-S238
Closed Access | Times Cited: 27
Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024

Cardiology Discovery (2025)
Open Access | Times Cited: 3
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure
Muhammad Shahzeb Khan, Gregg C. Fonarow, Darren K. McGuire, et al.
Circulation (2020) Vol. 142, Iss. 12, pp. 1205-1218
Open Access | Times Cited: 99
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trials
Husam M. Salah, Subhi J. Al’Aref, Muhammad Shahzeb Khan, et al.
American Heart Journal (2020) Vol. 232, pp. 10-22
Closed Access | Times Cited: 98
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
Sheyu Li, Per Olav Vandvik, Lyubov Lytvyn, et al.
BMJ (2021), pp. n1091-n1091
Open Access | Times Cited: 90
Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Elisabetta Patorno, Phyo T. Htoo, Robert J. Glynn, et al.
Annals of Internal Medicine (2021) Vol. 174, Iss. 11, pp. 1528-1541
Open Access | Times Cited: 71
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Rita R. Kalyani
New England Journal of Medicine (2021) Vol. 384, Iss. 13, pp. 1248-1260
Closed Access | Times Cited: 69
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Michelle D. Kelsey, Adam J. Nelson, Jennifer B. Green, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 18, pp. 1849-1857
Open Access | Times Cited: 66
Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts
Raffaele Marfella, Nunzia D’Onofrio, Maria Consiglia Trotta, et al.
Metabolism (2021) Vol. 127, pp. 154936-154936
Open Access | Times Cited: 65
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, et al.
Circulation Journal (2021) Vol. 85, Iss. 12, pp. 2252-2291
Open Access | Times Cited: 59
Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Adam J. Nelson, Emily C. O’Brien, Lisa A. Kaltenbach, et al.
JAMA Network Open (2022) Vol. 5, Iss. 2, pp. e2148030-e2148030
Open Access | Times Cited: 56
Sex Differences in Cardiovascular Consequences of Hypertension, Obesity, and Diabetes
Judith G. Regensteiner, Jane E.B. Reusch
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 15, pp. 1492-1505
Open Access | Times Cited: 56
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Kamil F. Faridi, Elias J. Dayoub, Joseph S. Ross, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 25, pp. 2516-2525
Open Access | Times Cited: 47
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care
Kim K. Birtcher, Larry A. Allen, Jeffrey L. Anderson, et al.
Journal of the American College of Cardiology (2022) Vol. 81, Iss. 3, pp. 292-317
Open Access | Times Cited: 42
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
Ronald Goldenberg, Alice Cheng, Tess Fitzpatrick, et al.
Stroke (2022) Vol. 53, Iss. 5, pp. 1813-1822
Open Access | Times Cited: 39
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
João Sérgio Neves, Francisco Vasques‐Nóvoa, Marta Borges‐Canha, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 189-197
Open Access | Times Cited: 39
Cholesterol Metabolism in Aging and Age-Related Disorders
Gesine Saher
Annual Review of Neuroscience (2023) Vol. 46, Iss. 1, pp. 59-78
Open Access | Times Cited: 33
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
João Sérgio Neves, Marta Borges‐Canha, Francisco Vasques‐Nóvoa, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 6, pp. 517-525
Closed Access | Times Cited: 33
The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study
Mark Ayoub, Carol Faris, Tajana Juranovic, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1625-1625
Open Access | Times Cited: 12
Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Aftab Ahmad, Hani Sabbour
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database
Stephen A. Firkins, Vibhu Chittajallu, Bailey Flora, et al.
Obesity Surgery (2024) Vol. 34, Iss. 5, pp. 1415-1424
Closed Access | Times Cited: 8
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Luis A. Rodríguez, Holly Finertie, Romain Neugebauer, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100759-100759
Open Access | Times Cited: 8

Scroll to top